𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4

✍ Scribed by Vince, Bradley; Hill, John M.; Lawitz, Eric J.; O’Riordan, William; Webster, Lynn R.; Gruener, Daniel M.; Mofsen, Ricky S.; Murillo, Abel; Donovan, Eileen; Chen, Jie; McCarville, Joseph F.; Sullivan-Bólyai, John Z.; Mayers, Douglas; Zhou, Xiao-Jian

Book ID
122225654
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
857 KB
Volume
60
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Multiple ascending dose study of BMS-790
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
✍ Richard E. Nettles; Min Gao; Marc Bifano; Ellen Chung; Anna Persson; Thomas C. M 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 282 KB

Abbreviations: AE, adverse event; AUC, area under the plasma concentration time curve; AUC (TAU) , AUC over 12-hour dosing interval for 30 mg twice daily; C min , minimum observed plasma concentration; C max , maximum observed plasma concentration; C trough , trough concentrations; CLT/F, apparent t

Mutations in the NS5A gene of hepatitis
Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b
✍ Hofgärtner, Wolfgang T.; Polyak, Stephen J.; Sullivan, Daniel G.; Carithers, Rob 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 310 KB 👁 3 views

Previous studies from Japan have described an association between a conserved sequence within the hepatitis C virus (HCV) genome and resistance to interferon (IFN) therapy for patients infected with HCV genotype 1b [